Dysregulation of Redox Status in Urinary Bladder Cancer Patients.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI

The alteration of redox homeostasis constitutes an important etiological feature of common human malignancies. We investigated DNA damage, selenium (Se) levels and the expression of cytoprotective genes involved in (1) the KEAP1/NRF2/ARE pathway, (2) selenoprotein synthesis, and (3) DNA methylation and histone deacetylation as putative key players in redox status dysregulation in the blood of urinary bladder cancer (UBC) patients. The study involved 122 patients and 115 control individuals. The majority of patients presented Ta and T1 stages. UBC recurrence occurred within 0.13 to 29.02 months. DNA damage and oxidative DNA damage were significantly higher in the patients compared to the controls, while plasma Se levels were significantly reduced in the cases compared to the controls. Of the 25 investigated genes, elevated expression in the peripheral blood leukocytes in patients was observed for NRF2 , GCLC , MMP9 and SEP15 , while down-regulation was found for KEAP1, GSR, HMOX1, NQO1, OGG1 , SEPW1, DNMT1, DNMT3A and SIRT1. After Bonferroni correction, an association was found with KEAP1, OGG1, SEPW1 and DNMT1 . Early recurrence was associated with the down-regulation of PRDX1 and SRXN1 at the time of diagnosis. Peripheral redox status is significantly dysregulated in the blood of UBC patients. DNA strand breaks and PRDX1 and SRXN1 expression may provide significant predictors of UBC recurrence.

Genes Nutr. 2012 Apr;7(2):127-37. (PMID: 21898179)
Cochrane Database Syst Rev. 2011 May 11;(5):CD005195. (PMID: 21563143)
Mol Cell Biol. 2005 Jun;25(12):4914-23. (PMID: 15923610)
Antioxid Redox Signal. 2018 Nov 1;29(13):1273-1292. (PMID: 28816066)
Oxid Med Cell Longev. 2016;2016:5710403. (PMID: 26649138)
Transl Psychiatry. 2015 Aug 04;5:e614. (PMID: 26241352)
Cell Mol Life Sci. 2009 Aug;66(15):2457-78. (PMID: 19399585)
Mol Brain. 2016 May 28;9(1):61. (PMID: 27234294)
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3410-5. (PMID: 11248092)
J Natl Cancer Inst. 2003 Sep 3;95(17):1312-9. (PMID: 12953085)
DNA Repair (Amst). 2007 Jan 4;6(1):45-60. (PMID: 16982217)
Physiol Rev. 2018 Jul 1;98(3):1169-1203. (PMID: 29717933)
J Biol Chem. 2005 Feb 4;280(5):3125-8. (PMID: 15590625)
Cancer Prev Res (Phila). 2017 Oct;10(10):588-597. (PMID: 28851690)
Oncol Rep. 2006 Sep;16(3):521-31. (PMID: 16865252)
J Natl Cancer Inst. 2003 Apr 2;95(7):540-7. (PMID: 12671022)
J Nutr. 2003 Sep;133(9):2721-7. (PMID: 12949356)
Cancer Chemother Pharmacol. 2010 Aug;66(3):467-74. (PMID: 19940992)
Annu Rev Biochem. 2017 Jun 20;86:715-748. (PMID: 28441057)
Sci Rep. 2018 Aug 27;8(1):12846. (PMID: 30150714)
Cochrane Database Syst Rev. 2018 Jan 29;1:CD005195. (PMID: 29376219)
Carcinogenesis. 2010 Jan;31(1):90-9. (PMID: 19793802)
Toxicol Mech Methods. 2019 Feb;29(2):119-127. (PMID: 30273082)
FEBS Lett. 2002 Apr 24;517(1-3):225-8. (PMID: 12062442)
Med Sci (Basel). 2020 Mar 13;8(1):. (PMID: 32183076)
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1896-901. (PMID: 12578971)
Arch Biochem Biophys. 2017 Mar 1;617:48-59. (PMID: 27495740)
Future Oncol. 2010 Sep;6(9):1433-60. (PMID: 20919828)
Clin Transl Oncol. 2020 Mar 18;:. (PMID: 32189139)
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7004-9. (PMID: 21487000)
Cancer Res. 2004 Sep 15;64(18):6424-31. (PMID: 15374950)
Nucleic Acids Res. 2010 Sep;38(17):5718-34. (PMID: 20460467)
Biochemistry. 2012 Oct 2;51(39):7740-54. (PMID: 22934964)
J Biol Chem. 2012 Aug 10;287(33):27371-9. (PMID: 22730327)
Biol Trace Elem Res. 2017 Jul;178(1):22-28. (PMID: 27957666)
Clin Chim Acta. 2012 May 18;413(9-10):847-54. (PMID: 22349600)
Eur J Nutr. 2017 Jun;56(4):1597-1607. (PMID: 27015911)
Carcinogenesis. 2007 Nov;28(11):2398-403. (PMID: 17602169)
Clin Chem Lab Med. 2009;47(9):1125-32. (PMID: 19728855)
Cancer Res. 2006 Jul 1;66(13):6800-6. (PMID: 16818657)
Ophthalmic Genet. 2017 Sep-Oct;38(5):446-450. (PMID: 28129013)
Nature. 2014 Mar 20;507(7492):315-22. (PMID: 24476821)
Toxicol Appl Pharmacol. 2009 Oct 1;240(1):8-14. (PMID: 19538980)
Genome Res. 2004 Oct;14(10B):2121-7. (PMID: 15489334)
Biol Trace Elem Res. 2015 Oct;167(2):236-41. (PMID: 25846212)
Biochim Biophys Acta. 2015 May;1853(5):1087-95. (PMID: 25721765)
Psychoneuroendocrinology. 2020 Apr;114:104600. (PMID: 32062372)
Environ Int. 2018 Aug;117:69-81. (PMID: 29727754)
Exp Cell Res. 1988 Mar;175(1):184-91. (PMID: 3345800)
Cancer Lett. 2015 Oct 1;366(2):150-9. (PMID: 26170166)
Trends Biochem Sci. 2014 Apr;39(4):199-218. (PMID: 24647116)
J Cell Mol Med. 2017 Jan;21(1):193-202. (PMID: 27653015)
Cancer Res. 2018 Sep 1;78(17):5124-5134. (PMID: 29986997)
Neoplasma. 2013;60(2):123-8. (PMID: 23259779)
Urol Oncol. 2018 May;36(5):241.e15-241.e23. (PMID: 29426697)
Mutagenesis. 2020 Feb 13;35(1):5-18. (PMID: 31294794)
Mutat Res. 1993 Jul;288(1):47-63. (PMID: 7686265)
Physiol Rev. 2014 Jul;94(3):739-77. (PMID: 24987004)
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2407-15. (PMID: 20807831)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Anal Cell Pathol (Amst). 2015;2015:419561. (PMID: 26199857)
Clin Chim Acta. 2006 Mar;365(1-2):30-49. (PMID: 16214123)
Int Immunopharmacol. 2018 Aug;61:37-44. (PMID: 29803135)
PLoS One. 2011;6(10):e26905. (PMID: 22046403)
J Trace Elem Med Biol. 2015 Apr;30:102-6. (PMID: 25524402)
Mutat Res. 2019 Jul;843:95-110. (PMID: 31421745)
Cancer. 2011 Nov 15;117(22):5221-33. (PMID: 21523767)
Biochem Biophys Res Commun. 2011 Sep 16;413(1):36-40. (PMID: 21875573)
Toxicol Appl Pharmacol. 2010 Apr 1;244(1):4-15. (PMID: 20122947)

OPUS 2012/05/B/NZ5/01406 Narodowe Centrum Nauki; 14.5 Nofer Institute of Occupational Medicine

Keywords: DNA damage; DNA methylation and histone deacetylation; NRF2-target genes; blood; comet assay; gene expression; recurrence; selenium; selenoproteins; urinary bladder cancer

Date Created: 20200528 Latest Revision: 20200928

20240829

PMC7280975

10.3390/cancers12051296

32455559